


MSTS Newsletter

Volume 24, Summer 2019

Inside this Issue

President's Report	1	Membership Committee	5	Fellowship Committee	7
MSTS Executive Committee	1	Evidence Based Medicine Committee.	5	Sarcoma Strong Corner	9
Research Committee	2	Education Committee.	5	Practice Management Committee	10
Treasurer's Report	2	MSTS & OREF Donations	7	Committee for Registry Development.	10
2019 Annual Meeting	3	Research Committee	7	Future Meetings	10

President's Report – R. Lor Randall, MD, FACS



R. Lor Randall, MD, FACS

With the waning days of summer we are pleased to present you with the summer MSTS newsletter. The Executive Committee has been busy on multiple fronts. The volunteerism by the membership has never been greater. I am so impressed by the enthusiasm and commitment that members continually demonstrate to steward our mission and improve our field. The dedication is inspiring. I would

like to recognize Kerri Mink who has assumed the responsibility of managing our Society. She has transitioned smoothly and we are grateful for her quick learn! Amy Sherwood handled the mantle with grace and expertise during the process of hiring a new manager. Thanks to you both! Of course, Deborah Meyer, has once again been our backbone in the planning of our Annual Meeting. Anna Greene has also proved invaluable in helping us with our fiduciary responsibility. We are well positioned into the future with these four at the helm. Thank you!

Specialty Day 2019 was great success thanks to Megan Anderson and Pietro

Ruggieri. The input from Nick Bernthal and David King was also very much appreciated. We had a very dynamic and engaging presentation, entitled *Look for the Light: Applying Space Engineering Techniques to Osteosarcoma Genomics* by Theresa Beech. She demonstrated the power of harnessing personal tragedy to drive therapeutic innovation. We are very grateful to her for sharing her personal journey and time with us. Additionally, It was inspiring to see all the amazing talent on stage and in the audience asking questions during the Challenging Case session. It was truly a great Specialty Day. Thanks to all of the participants and attendees.

Continued on page 2

MSTS Executive Committee

President

R. Lor Randall, MD, FACS
rlrandall@ucdavis.edu

President-Elect

Joel Mayerson, MD
joel.mayerson@osumc.edu

Secretary

Carol D. Morris, MD
cmorri61@jhmi.edu

Treasurer

Michael P. Mott, MD
mmott2@hfhs.org

Immediate Past President

Joseph Benevenia, MD
benevejo@rutgers.edu

Past President

Robert H. Quinn, MD
quinnr@uthscsa.edu

Education Committee

Valerae O. Lewis, MD
volewis@mdanderson.org

Research Committee

Francis Young Lee, MD, PhD
francis.lee@yale.edu

Membership Committee

Brian Brigman, MD
brian.brigman@duke.edu

Members-at-Large

Nicholas Bernthal, MD
nbernthal@mednet.ucla.edu

Gary E. Friedlaender, MD
gary.friedlaender@yale.edu

MSTS Headquarters

9400 W. Higgins Rd., Suite 500 Rosemont, IL 60018 info@msts.org 847/698-1625 fax: 847/268-9574

President's Report, cont'd from pg. 1

As usual, our committees have been quite busy and we are very grateful for all their efforts. The Education Committee is moving on several novel fronts. They are collaborating with the Academy in building a MSTS Channel in the Orthopaedic Video Theater (OVT). Raj Rajani has also been working with the Fellowship Committee to develop an orthopaedic oncology mini traveling fellowship for fellows still in training - stay tuned. A new MSTS branded OKU is also in the works. The Research Committee has been incredibly active with Chair Francis Lee as the driving force. Please look to his report on all the tremendous activity. Sarcoma Strong, under the leadership of Matt DiCaprio, continues to help our mission by supporting the research efforts. We cannot thank Dr. DiCaprio enough for all of his work!

The finances of the organization are in good standing. We are grateful for the stewardship of Mike Mott as Treasurer. I am pleased to announce that for the upcoming Portland meeting we have surpassed our budget, thanks to the tremendous showing of our industry partners. Please make sure to thank your local representatives and visit the booths and product theatres in Portland. An exciting development that has been overseen by Raj Rajani and the Fellowship Committee is that starting in 2021, MSTS will oversee our own Fellowship Match process. We are grateful to the SF Match for their management over the years. We are also investigating establishing MSTS as an accreditation body for our fellowships. Again, please stay tuned.

Please do take the time to read about all the exciting developments that are being spearheaded by MSTS committees. Hopefully you will be as pleased as I am to see our organization striving to make a difference in so many ways.


Finally, Portland is almost here! We have an exciting program in store. Thanks are not enough to James Hayden and Yee-Cheen Duong for their tenacity in developing a first rate program. Our Presidential speaker will be internationally recognized bone endocrinologist Theresa Guise, MD. We will have a trans-disciplinary symposium focusing on Adolescent and Young Adult sarcoma

related issues. Oregon Health Sciences University was effectively the "birthplace" of this movement in the United States. The "Teach the Teacher" session is sure to be a highlight as well. Our group dinner will feature local food, beer and wine, in a relaxed environment, as can only be experienced in zany Portland. Look forward to seeing you all out west!
Humbly,
Lor

Research Committee - Francis Young Lee, MD, PhD, Chair

MSTS Mentored Research and Scholar Development Program Award Announcement

MSTS is enthusiastic about nurturing a culture of discovery and fostering mentorship for our society. MSTS has established a new Mentored Research and Scholar Development Program Award. The purpose of the award is to foster mentorship, enhance collaborative research and facilitate career advancement for young MSTS Candidate/Associate/Full Members. Please click [here](#) for further information, an award description and sample grants.



OUR MISSION

The Musculoskeletal Tumor Society will advance the science of orthopaedic oncology and promote high standards of patient care through excellence in education and research.

OUR VISION

The Musculoskeletal Tumor Society will be a recognized authority on all aspects of orthopaedic oncology, an influential participant in policy-making for orthopaedic oncology services, and responsive to the needs of orthopaedic oncologists and their patients.

Treasurer's Report - Michael P. Mott, MD

Greetings MSTS members! As the 2019 fiscal year comes to an end, I am happy to report that our Society maintains strong financial health. With our new initiatives and endeavors, we have had significant increases in our administrative overhead. Fortunately, we have been able to maintain healthy returns from partnerships and sponsorships, as well as gains in our Annual Meeting and Specialty Day. These efforts combined with our portfolio investment returns, have served to allow us to meet and fund the increased costs associated with these projects. Our restricted funds, including the Hatcher Fellowship and the Sarcoma Research/ Sarcoma Strong Fund, also remain with acceptable balances.

It is important to note the ability to support research proposals is largely met through the generosity and efforts of Matt DiCaprio's Sarcoma Strong fundraising event, which was held on August 17th. Thank you to Matt and to all those who participated and donated! Our MSTS designated OREF giving has been particularly low this year compared to previous years. OREF giving is another way to make meaningful contributions to the research effort of the society and I would encourage active members to do so if feasible.

As always, the details of our income and expenses will be reviewed at our Annual Meeting in October. Fortunately, our society has been buoyed in the past few years by healthy investment gains and this has allowed us to safely fund an increasing number of endeavors. However, we need to be prepared should that financial environment change. If anyone has any question or suggestions regarding our finances, please do not hesitate to contact me at mmott2@hfhs.org.

2019 Dues Renewal

Friendly Reminder – Please submit payment for your 2019 membership dues. Pay your 2019 Membership Dues [online](#).

Forgot your login information? Contact MSTS for assistance at 847/698-1625 or info@msts.org.

Annual Meeting Program at a Glance

– James B. Hayden, MD & Yee-Cheen Doung, MD, Co-Chairs

WEDNESDAY, OCTOBER 2

1:00 PM – 6:30 PM	REGISTRATION	Salon A-E Foyer
1:00 PM – 5:00 PM	POSTER SET UP	Ballroom Foyer
	TECHNICAL EXHIBIT BOOTH SET UP	Salon F-I
3:00 PM – 6:00 PM	MORI/MSTS YOUNG MEMBERS' SESSION	Eugene
6:30 PM – 8:30 PM	WELCOME RECEPTION	Mt. Hood Room

THURSDAY, OCTOBER 3

6:30 AM – 5:30 PM	REGISTRATION	Salon A-E Foyer
7:00 AM – 8:30 AM	BREAKFAST	Salon F-I
7:00 AM – 5:30 PM	POSTER/TECHNICAL EXHIBITS	Ballroom Foyer / Salon F-I
7:30 AM	INTRODUCTION and WELCOME	Salon A-E
7:45 AM	EVALUATION OF NEW BONE LESIONS	Salon A-E
8:00 AM	SESSION I: REGISTRY	Salon A-E
8:25 AM	SESSION II: SOFT TISSUE SARCOMA	Salon A-E
9:40 AM – 10:10 AM	PRODUCT THEATER - Onkos Surgical	Portland
9:40 AM – 10:10 AM	POSTER VIEWING	Ballroom Foyer
9:40 AM – 10:10 AM	Break	Salon F-I
10:10 AM	SESSION III: BONE TUMORS	Salon A-E
10:35 AM	SESSION IV: SURGICAL TREATMENT	Salon A-E
11:50 AM – 1:00 PM	LUNCH	Salon F-I
11:50 AM – 12:10 PM	PRODUCT THEATER - Artoss, Inc.	Portland
11:50 AM – 1:00 PM	POSTER VIEWING	Ballroom Foyer
1:00 PM	SESSION V: PANEL DISCUSSION: ADOLESCENTS AND YOUNG ADULTS	Salon A-E
1:40 PM	SESSION VI: YOUNG ADULTS	Salon A-E
2:35 PM – 3:05 PM	POSTER VIEWING	Ballroom Foyer
2:35 PM – 3:05 PM	Break	Salon F-I
2:35 PM – 2:55 PM	PRODUCT THEATER - Stryker	Portland
3:05 PM – 3:50 PM	MSTS BUSINESS MEETING - MSTS Members Only	Salon A-E
3:50 PM	SESSION VII: RESEARCH	Salon A-E
5:05 PM	SESSION VIII: MISCELLANEOUS	Salon A-E
5:30 PM	MEETING ADJOURNS	
6:00 PM – 10:00 PM	SOCIAL EVENT - PORTLAND WORLD TRADE CENTER	



		Salon A-E Foyer
		Salon F-I
		Ballroom Foyer / Salon F-I
		Salon A-E
		Salon A-E
		Portland
		Ballroom Foyer
		Salon F-I
		Salon A-E
		Salon A-E

FRIDAY, OCTOBER 4

6:30 AM – 8:30 AM	REGISTRATION	Salon A-E Foyer
7:00 AM – 8:30 AM	BREAKFAST	Salon F-I
7:00 AM – 11:00 AM	POSTERS/TECHNICAL EXHIBITS	Ballroom Foyer / Salon F-I
7:30 AM	SESSION IX: METASTATIC	Salon A-E
8:45 AM – 9:45 AM	PRESIDENTIAL GUEST LECTURER – Theresa A. Guise, MD “CANCER, BONE, MUSCLE AND METABOLISM: WHAT’S THE CONNECTION?”	Salon A-E
9:45 AM – 10:05 AM	PRODUCT THEATER - Onkos Surgical	Portland
9:45 AM – 10:15 AM	POSTER VIEWING	Ballroom Foyer
9:45 AM – 10:15 AM	Break	Salon F-I
10:15 AM	SESSION IX: METASTATIC, continued	Salon A-E
11:30 AM	SESSION X: TEACH THE TEACHER	Salon A-E
12:30 PM	MEETING ADJOURNS	



Presidential Guest Lecturer



Theresa A. Guise, MD

Dr. Theresa A. Guise is the Jerry and Peggy Throgmartin Professor of Oncology, Professor of Medicine and Pharmacology at the Indiana School of Medicine, where she directs a basic and translational research program on the effects of cancer and cancer treatment on bone, muscle and metabolism.

She is currently principal investigator in several grant-funded research projects from the NIH and the Department of Defense. Dr. Guise’s clinical interests encompass diseases of calcium and bone metabolism and musculoskeletal health in cancer patients. She has authored over 150 peer-reviewed articles, has an h-index of 66 and over 22,000 lifetime citations. She has trained 30 postdoctoral fellows, 3 PhD students, 8 junior faculty and hosted 30 summer research students over the past 27 years. Her laboratory has been consistently funded by the NIH, DOD (breast cancer, prostate cancer and neurofibromatosis) as well as by Susan G. Komen, Prostate Cancer Foundation, V-Foundation, Mary K. Ash, pharmaceutical companies and philanthropy.

THE POWER OF PERSONALIZATION

Driving significant advancements in musculoskeletal oncology.

We believe individuals with cancer requiring surgery deserve innovation designed specifically for them. Our patient-specific My3D platform enables you to create a treatment plan for each of your patients which can include joint sparing resection guides, anatomical models, and patient-matched allograft.



PRECISION ORTHOPAEDIC ONCOLOGY.

www.onkossurgical.com

2019 MSTs Diamond Level Exhibitor

www.facebook.com/onkossurgical | www.linkedin.com/company/onkossurgical | twitter.com/onkossurgical | #goodenoughisnotgoodenough

All registered marks and trademarks are marks of ONKOS SURGICAL. A surgeon should rely exclusively on his or her own professional medical/clinical judgment when deciding which particular product to use when treating a patient. ONKOS SURGICAL does not prescribe medical advice and advocates that surgeons be trained in the use of any particular product before using it in surgery. A surgeon must always refer to the product label and/or instructions for use before using any ONKOS SURGICAL product.

CORP 08.23.19 VO

Membership Committee - Brian Brigman, MD, Chair

The Membership Committee is here to serve you! We are constantly looking for ways to improve and enhance your membership experience. If you have any ideas which you feel can improve membership in the MSTs, please feel free to contact me or any membership committee member.

We need you to stay in touch! Please visit the MSTs website and make sure all your information is up to date so that we can keep you informed on society events and important announcements.

The Membership Committee would like to welcome the following new members, and recognize MSTs members who have advanced their membership, and have been approved by the Executive Committee. We look forward to your active participation in MSTs.

ACTIVE Members

Johnathan A. Forsberg, MD, PhD
Drew Douglas Moore, MD
Shawn L. Price, MD
Nicholas Tedesco, MD
Melissa Zimel, MD

CANDIDATE Members

Colin Anderson, MD
Alan Blank, MD
Richard (Trey) William Gurich, Jr., MD
Louis B. Jones, MD
Stella Joo Lee, MD
Dustin Lybeck, MD
Jay N. Patel, MD
Adam Neal Wooldridge, MD
Manaf H. S. Younis, MD

RESIDENT Members

Motaz AlAqeel, MD
Ashley Bee Anderson, MD
Michael Eckhoff, MD
Joshua Johnson, MD
Alexander Leandros Lazarides, MD
Tierney A. Shannon, MD
Sophia A. Traven, MD

Learn more about membership requirements and classes of membership by visiting the MSTs website. Your Membership Committee consists of Drs. Brian Brigman - brian.brigman@duke.edu, Nicholas Bernthal - NBernthal@mednet.ucla.edu, Cynthia Emory - clemory@wakehealth.edu, Howard Rosenthal - hrosenthal@kumc.edu, Pietro Ruggieri - pietro.ruggieri@unipd.it and Joel Sorger - joel.sorger@cchmc.org.

Evidence Based Medicine Committee - Felasfa Wodajo, MD, Chair

The EBM Committee has continued to expand collaboration with other medical and surgical societies. This multi-disciplinary approach allows us to share and refine ideas, as well as increasing the visibility of our society.

A funded project to produce a Clinical Practice Guideline (CPG) on the treatment of metastatic bone disease in the femur is now moving towards the writing phase. The Guideline is led by MSTs in a three-way collaboration with the American Society of Therapeutic Radiation (ASTRO) and the American Society of Clinical Oncology (ASCO), each of whom contributed members to the workgroup. The Principal Investigators are Felasfa Wodajo and Patrick Getty.

ASTRO recently invited MSTs to collaborate on the development of a guideline on Radiation Therapy for Treatment of Soft Tissue Sarcoma. The Evidence Based Medicine Committee will be forwarding to ASTRO a slate of nominees to represent MSTs. The project will start in September 2019 and will take approximately 18 months to complete.

An EBM produced information statement led by Eric Henderson on early decision-making and referral indications for newly identified bone lesions has been co-endorsed by the American College of Radiology (ACR). The intended audience

is primary care physicians and non-oncologic orthopedic surgeons. Dr. Henderson also proposed to ACR a project to develop a standardized radiology report template for potentially neoplastic bone lesions. The ACR accepted the proposal and a multidisciplinary workgroup, which includes Dr. Henderson and other MSTs members, has begun drafting the guideline. One goal is that future radiography reports will provide referring physicians a more focused differential diagnosis as well as specific recommendations for patient management.

Finally, the EBM Committee proposed to ASCO a collaborative project to develop a practice guideline on the use of Adjuvant Chemotherapy in Non Metastatic Soft Tissue Sarcoma. We have obtained preliminary approval, with ASCO as lead organization. This project is led from MSTs by Steven Thorpe. If approved, this project will likely begin in Winter 2019.

The EBM Committee serves the MSTs membership. If you have any ideas for clinical practice guidelines, appropriate use criteria, information statements or quality improvement projects, please do not hesitate to reach out to myself (wodajo@sarcoma.md) or any of the EBM Committee Members.

Education Committee - Valerae O. Lewis, MD, Chair

MSTS Annual Meeting

The 2019 MSTs Annual Meeting in Portland is quickly approaching. Program Chair James Hayden has put together an excellent meeting. 174 abstracts were submitted and we will have 61 presentations and 41 posters. Theresa Guise will deliver the Presidential Lecture: *Cancer, Bone, Muscle and Metabolism: What's the Connection?* There will be two panel discussions: Adolescents and Young Adults (AYA) Panel and "Teaching the Teacher." It is shaping up to be a meeting not to miss!

AAOS Annual Meeting

The AAOS Annual Meeting will be held

in Orlando, Florida. We are offering 5 all new Tumor Instructional Course Lectures and 1 symposium - date and time TBA.

1. Bone Tumors in the Young Person: Diagnosis and Management - Moderator: *Wakenda Tyler*
2. Management of Metastatic Disease to Bone - Moderator: *Emily Carmody*
3. Soft Tissue Masses: A Visual Guide To The Good, The Bad and The Ugly - Moderator: *Ginger Holt*
4. Tumors and Tumor-Like Conditions that Every Orthopedist Should Be Aware Of - Moderator: *Lor Randall*

Continued on page 6



Global Modular Replacement System

One system, one vision, one solution

- Based on the principles of KRH, MRH, and MRS systems with 35 years of established performance
- GMRS modular components are designed to restore the articular surface, bony defects, and leg length discrepancy
- Various configurations provide choices to help meet patients' needs

A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery.

The information presented is intended to demonstrate the breadth of Stryker's product offerings. A surgeon must always refer to the package insert, product label and/or instructions for use before using any of Stryker's products. The products depicted are CE marked according to the Medical Device Directive 93/42/EEC. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your sales representative if you have questions about the availability of Stryker's products in your area.

Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: GMRS, Stryker. All other trademarks are trademarks of their respective owners or holders.

5. How to Stay Out of Trouble in the Pediatric/Adolescent Patient - Moderator: *Val Lewis*
6. Pathological Fractures 2020: Case-Based Learning for Newest Knowledge and Techniques for Effective Management - Moderator: *Francis Lee*

Once again, there are 2 scientific podium sessions, a poster tour and a Video Theater presentation focusing on tumor-related topics. Remember, handouts are only available electronically via My Academy app or from your registration record. Handouts for all Instructional Courses will be available one week prior to the meeting.

Once again, you will be able to purchase an Education Track Package from the AAOS. This track identifies the best sessions for your level of expertise. There are two Musculoskeletal Oncology Tracks available. Track packages are only available for advanced purchase. Visit www.aaos.org/annual to purchase.

Specialty Day

Led by Chair and Co-Chairs Pietro Ruggieri and Nick Bernthal, 2020's Specialty Day will once again prove to be "one for the books." Covering a variety of topics from career development to complex problem solving, Dr. Ruggieri and team have organized an excellent, not to be missed day.

OVT

Orthopaedic Video Theater – The AAOS OVT provides trusted, relevant surgical videos from globally renowned experts across the orthopaedic landscape. We are in the process of developing a MSTS Channel. If you are interested in developing a peer reviewed surgical video to contribute to the musculoskeletal oncology collection, please contact the Education Committee. This will be an excellent resource for attendings, residents and fellows.

MSTS and OREF Donations 2018 & 2019

MSTS extends our sincere appreciation to the following members who donated over the past year to MSTS or OREF. Your support helps to ensure that MSTS continues to fulfill the Vision and Mission of our Society.

Megan E. Anderson, MD
Nicholas M. Bernthal, MD
Alan T. Blank, MD, MS
Gary D. Bos, MD
Scot A. Brown,
Emily Carmody, MD
Edward Y. Cheng, MD
Felix H. Cheung, MD
Kenneth J. Chirba
Matthew W. Coleman, MD
Timothy A. Damron, MD
Mark C. Gebhardt, MD
David S. Geller, MD
Steven Gitelis, MD
Gregory N.M. Hrasky, MD
John H. Healey, MD, FACS
David Hennessy, MD
Bang H. Hoang, MD
James O. Johnston, MD
David M. King, MD

Joseph M. Lane, MD
Adam S. Levin, MD
Patrick P. Lin, MD
Bennie G. Lindeque, MD
Joel L. Mayerson, MD
Susan M. McDowell, MD
Carol D. Morris, MD
Michael P. Mott, MD
Vincent Y. Ng, MD
Lukas M. Nystrom, MD
Richard O'Donnell, MD
Christian Ogilvie, MD
Theodore W. Parsons, III, MD, FACS
Robert H. Quinn, Jr. MD
R. Lor Randall, MD, FACS
Richard Terek, MD, FACS
Wakenda K. Tyler, MD, FCS
Kristy L. Weber, MD
Rosanna Wustrack, MD
Melissa Zimel, MD

Donations received September 2018 to September 9, 2019

Fellowship Committee – Rajiv Rajani, MD, Chair

Welcome from the Fellowship Committee. The Committee serves to improve the quality of our trainees pursuing a career in orthopaedic oncology. We also serve to provide oversight and guidance with the match process, the Accreditation Council for Graduate Medical Education (ACGME), while assisting fellowship directors as they navigate guidelines. In the past year, the committee has focused on improving the transparency of the application process. We have asked programs to make their interview dates known as early as possible and to attempt to coordinate interview dates with geographically similar programs. This will allow for applicants to minimize spending and time away from their current training programs.

The Committee has explored developing an accreditation position from the MSTS. Currently, POSNA and OTA provide accreditation for fellowships, similarly to the ACGME. The MSTS has considered this for years but has not pursued this for a variety of reasons. Conversations continue

and if you have an opinion on this matter, please do not hesitate to reach out to rajani@uthscsa.edu.

Currently, oncology fellowships are grouped with the hip and knee reconstruction fellowships through SF Match. As oncology fellowships have grown in number, we now have nearly as many fellowships as the shoulder and elbow society which has their own application process. In 2020, expect a change in this process as we continue to talk to AAKHS about separating from them for the application and match process. Having our own application process will better allow us to focus on issues that pertain to oncology applicants and fellowship directors.

The ACGME is currently taking feedback on recent modifications to the MSK Oncology Fellowship Program Requirements. The Fellowship Committee has provided updates but require final approval which should occur by the end of the year after a delay secondary to ACGME changes. We look forward to seeing you in Portland!



OSS™ Orthopedic Salvage System

DELIVERING A COMPREHENSIVE SOLUTION FOR SIGNIFICANT BONE LOSS.

The Orthopedic Salvage System is designed to provide a comprehensive modular platform giving surgeons intraoperative flexibility often required during challenging reconstructions.



All content herein is protected by copyright, trademarks, and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet. This material is intended for health care professionals. Distribution to any other recipient is prohibited. For indications, contraindications, warnings, precautions, potential adverse effects and patient counselling information, see the package insert or contact your local representative; visit www.zimmerbiomet.com for additional product information. Check for country product clearances and reference product specific instructions for use. Rx Only. Not for distribution in France. © 2019 Zimmer Biomet

 **Legal Manufacturer**
Biomet Orthopedics
P.O. Box 587
56 E. Bell Drive
Warsaw, Indiana 46581-0587
USA

zimmerbiomet.com

Sarcoma Strong Corner

- Matthew R. DiCaprio, MD

The 6th Annual Sarcoma Strong 5k Run/Walk on August 17th in Albany, NY was a huge success. Our participant numbers continue to grow and we surpassed our goal of \$100,000 raised in 2019. We were able to accomplish this growth by collaboration with multiple institutions that were able to host inaugural events or expand on past experience. Besides our main event in Albany, we were joined by events in the following locations: Montefiore – led by David Geller and Bang Hoang, McMaster’s – led by Michelle Ghert, UCSF – led by Rosanna Wustrack, Henry Ford – led by Michael Mott, Summa Health – led by Scott Weiner.

Several other centers are in the process of organizing fundraising events and are being supported through my leadership with the MSTs Development of Research Funding Project Team. These include Rutgers led by Joseph Benevenia; MD Anderson at Cooper led by Tae Won Kim; Johns Hopkins and Sinai Hospital led by Carol Morris and Albert Aboulafia.

The Project Team is a new 2-year initiative of the society to explore strategies and make recommendations to the Committee on Research for enhancing the funding available for musculoskeletal research: Through coordination and expansion of existing fund-raising programs (Sarcoma Strong) and development of new regional and national approaches. Our primary goal is to engage more centers throughout North America that can help us sustain a funding source to uphold our research mission as a society. Working with the Executive Committee of MSTs, we will continue to support the \$25,000 Mentored Research and Scholar Development Awards, and Sarcoma Strong/MSTS \$50,000 research grants.



In 2017, our first \$100,000 Sarcoma Strong/MSTS grant was awarded to Dr. Bang Hoang for his project titled *Targeting MicroRNA by Flavokawain A (FKA) as Therapy for Osteosarcoma*. His research team has accomplished the following:

- microRNA-34 exerts anti-cancer activity in osteosarcoma cells.
- The drug FKA is an effective anti-metastatic agent, even at a relatively low dose. This anti-cancer mechanism of FKA appears to involve the Skp2-RhoA interaction.
- FKA enhances the expression of microRNA-34 and microRNA-203. Both microRNA-34 and 203 are involved in preventing the proliferation and spread of osteosarcoma cells.
- FKA reduces the expression of the oncogene Skp2, which is a known target of microRNA-203. These findings open up new avenues for us to block the action of Skp2, an important driver of osteosarcoma, to prevent tumor cells from spreading to the lungs.
- Skp2 results have been published recently in a high-impact journal: Down-Regulation of Skp2 Expression Inhibits Invasion and Lung Metastasis in Osteosarcoma. *Scientific Reports* 24;8(1):14294 (2018).



Because of the support from Sarcoma Strong, we have been awarded another grant from the Live for Others Foundation (2019 – 2021) to study the role of FKA and the proteasome in synovial sarcoma.

Any MSTs member who would like more information about starting a run or fundraising event at their institution can email me at dicaprm@amc.edu. Next year’s 5k event is set for August 15, 2020. Thank you for your support. Together we are Uniting the Sarcoma Fight!



Practice Management Committee

– Adam S. Levin, MD, Chair

It has been a busy year so far from a Practice Management standpoint. Together, with the AAOS and AAHKS, we have helped develop new codes for non-bioabsorbable antibiotic delivery implants, including antibiotic cement spacers. These have been surveyed and valued, and will likely become active in January 2020. In addition, we have also been supporting the AAOS's efforts regarding valuation of Evaluation and Management services, as well as the valuation of arthroplasty procedures. As many of our members may be aware, CMS has been adjusting the plans for documentation requirements for Evaluation and Management (E&M) Level of Service (LOS). Some of these changes have already gone into effect -- mostly related to easing the need to re-document information that is already in the medical record. That is a small, but recognizable victory for clinicians. The major changes will roll out in January 2021, and will likely have profound impact on documentation requirements for E&M services, the means of determining LOS, and the valuation of E&M services. We will work to prepare our members for these changes as we get closer to implementation of these changes. We are also developing content to be included on the MSTS website to assist members regarding coding and practice management considerations, as well as providing a forum for questions or concerns.

Please let us know if there are any additional practice management or coding questions or concerns that we can either answer or address in order to better suit the needs of our membership.

Committee for Registry Development

– Ben Miller, MD, Chair

The MSTS registry working group and the AAOS continue steady progress toward a society-wide registry. The six center (Iowa, Dartmouth, Ohio State, Stanford, Cleveland Clinic, and Johns Hopkins) pilot trial is nearing its successful conclusion and we anticipate enrolling additional centers in the spring of 2020. Many thanks

to all the hard work of the surgeon leaders at each of the pilot sites, and we look forward to expanding the effort over the coming months.

Visit the AAOS Registry Booth #12 at the Annual Meeting to learn more.

Future Meetings

2019 MSTS Annual Meeting

Date: October 2-4, 2019

Location: Marriott Portland Downtown Waterfront Hotel
Portland, Oregon



2020 MSTS Specialty Day

Date: March 28, 2020


Location: Orange County Convention Center
Orlando, Florida



2020 MSTS Annual Meeting

Date: October 7-9, 2020

Location: Hyatt Regency Columbus
Columbus, Ohio



Musculoskeletal Tumor Society

9400 W. Higgins Road, Suite 500 • Rosemont, IL 60018

website: www.MSTS.org

phone: 847/698-1625 e-mail: info@msts.org